system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: BACKGROUND, RESULTS. Meshes: Aging, Angiotensin II Type 1 Receptor Blockers, Animals, Benzimidazoles, Biomarkers, Blood Glucose, Cellular Senescence, Diabetes Mellitus, Echocardiography, Gene Expression Regulation, Hemodynamics, Insulin, Male, Mice, Mice, Inbred C57BL, Mice, Obese, Myocardium, Oncogene Protein v-akt, Phosphorylation, Proliferating Cell Nuclear Antigen, Retinoblastoma Protein, Ribosomal Protein S6 Kinases, Tetrazoles, Tumor Suppressor Protein p53, rho GTP-Binding Proteins.
user
Does angiotensin II receptor antagonist attenuate expression of aging markers in diabetic mouse heart? Context: Diabetes mellitus is an independent risk factor for heart failure. Diabetes mellitus causes other age-related cardiovascular diseases. We assessed the hypothesis that hearts from diabetic animals are associated with accelerated aging processes. We also examined the effect of an angiotensin II receptor blocker (ARB) on the expression of senescence-associated molecules. We administered an ARB (candesartan 10 mg/kg per day) or saline to diabetic db/db or control db/+ mice. The treatment was started when mice were 10-weeks-old, and continued for 15 weeks. Systolic function was impaired in db/db mice and candesartan improved cardiac function. The amount of phosphorylated Akt and S6 was decreased in saline-treated db/db mice, and candesartan treatment partially preserved phosphorylation. The amount of p21, p27, p53 or Rb was increased in the heart tissue of saline treated db/db mice. Candesartan treatment completely suppressed the increases of p21, p27, p53 and Rb.
assistant
An ARB improved cardiac function of diabetic animals, and this was accompanied by decreases of senescence-associated molecules in the myocardium. ARB may be a modality for heart failure patients with diabetes mellitus. Final Decision: yes